以奈达铂、顺铂为主治疗晚期非小细胞肺癌的对比分析  

作　　者：曹江[1] 

机构地区：[1]湖南省肿瘤医院药剂科,长沙410013

出　　处：《中华临床医学卫生杂志》2007年第4期3-5,共3页China Journal of Clinical Medicine Hygiene

摘　　要：目的观察比较含奈达铂与含顺铂联合化疗方案治疗晚期非小细胞肺癌的疗效和不良反应。方法我院收治的69例晚期非小细胞肺癌患者，奈达铂治疗组共34例，顺铂治疗组共35例，分析两组的近期疗效及毒副作用。结果奈达铂组与顺铂组的近期有效率分别为肺鳞癌35．00％和42．11％，肺腺癌35．71％和37．50％，两组无统计学差异（P〉0．5）；奈达铂组胃肠道反应（26．47％）发生率明显低于顺铂组（71．43％）（P〈0．01）；血小板下降奈达铂组（52．94％）明显高于顺铂组（34．29％）（P〈0．05）。结论奈达铂联合化疗方案近期疗效接近顺铂联合化疗方案，奈达铂组的毒副作用以骨髓抑制为主；顺铂组的毒副作用以胃肠道反应及早期肾功能异常为主。Objective To detect the efficacy and the side effect of the regimen for combined chemotherapy with nedaplatin and cisplatin in the treatment of advanced non-small cell lung carcinoma. Methods A total of 69 patients with advanced non-small cell lung carcinoma were divided into the nedaplatin group（n=34）and the traditional group（n=35）.Results The efficacy of nedaplatin group was 35.29% anti cisplatin group was 40.00%. There was no significant difference between the two groups in curative effect（P〉0.05）. Conclusion Nedaplatin group is an effective regimen for patients with advanced ovarian cancer, its efficacy is similar to that of cisplatin group phamide. The main side-effect of nedaplatin group is myelosuppression, while that of cisplatin group are gastrointestinal toxicity and nephrotoxicity. Other toxicities are rare.

关 键 词：奈达铂 顺铂 非小细胞肺癌 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]